JP2020515247A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020515247A5 JP2020515247A5 JP2019551983A JP2019551983A JP2020515247A5 JP 2020515247 A5 JP2020515247 A5 JP 2020515247A5 JP 2019551983 A JP2019551983 A JP 2019551983A JP 2019551983 A JP2019551983 A JP 2019551983A JP 2020515247 A5 JP2020515247 A5 JP 2020515247A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- antigen
- binding fragment
- cancer
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201710185400.8 | 2017-03-25 | ||
| CN201710185400.8A CN108623686A (zh) | 2017-03-25 | 2017-03-25 | 抗ox40抗体及其用途 |
| PCT/CN2018/080315 WO2018177220A1 (zh) | 2017-03-25 | 2018-03-23 | 抗ox40抗体及其用途 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020515247A JP2020515247A (ja) | 2020-05-28 |
| JP2020515247A5 true JP2020515247A5 (enExample) | 2021-08-19 |
| JP7046973B2 JP7046973B2 (ja) | 2022-04-04 |
Family
ID=63674253
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019551983A Expired - Fee Related JP7046973B2 (ja) | 2017-03-25 | 2018-03-23 | 抗ｏｘ４０抗体およびその使用 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US11498972B2 (enExample) |
| EP (1) | EP3604338A4 (enExample) |
| JP (1) | JP7046973B2 (enExample) |
| CN (2) | CN108623686A (enExample) |
| CA (1) | CA3056972A1 (enExample) |
| WO (1) | WO2018177220A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107474136B (zh) | 2016-06-08 | 2023-03-07 | 上海交通大学医学院 | 增强激动型抗体活性的抗体重链恒定区序列 |
| WO2018041119A1 (en) | 2016-08-31 | 2018-03-08 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animal with human or chimeric ox40 |
| CN107815465B (zh) * | 2016-08-31 | 2021-03-16 | 百奥赛图(北京)医药科技股份有限公司 | 人源化基因改造动物模型的制备方法及应用 |
| KR102776166B1 (ko) | 2017-08-07 | 2025-03-04 | 더 리전트 오브 더 유니버시티 오브 캘리포니아 | 안전한 세포 치료제를 생성하기 위한 플랫폼 |
| CN110305210B (zh) * | 2018-03-27 | 2023-02-28 | 信达生物制药(苏州)有限公司 | 新型抗体分子、其制备方法及其用途 |
| WO2020108463A1 (zh) * | 2018-11-26 | 2020-06-04 | 南京金斯瑞生物科技有限公司 | 人源化抗人ox40单克隆抗体及其制备方法和用途 |
| EP3898673A1 (en) * | 2018-12-21 | 2021-10-27 | 23Andme, Inc. | Anti-il-36 antibodies and methods of use thereof |
| CN111363040B (zh) * | 2018-12-25 | 2023-07-14 | 杭州翰思生物医药有限公司 | 抗ox40的单克隆抗体及其应用 |
| TWI793395B (zh) * | 2019-01-25 | 2023-02-21 | 大陸商信達生物製藥（蘇州）有限公司 | 結合ｐｄ-ｌ１和ｏｘ４０的雙特異性抗體 |
| CN110003338B (zh) * | 2019-04-16 | 2021-04-23 | 北京免疫方舟医药科技有限公司 | 抗ox40抗体及其应用 |
| CN110004177A (zh) * | 2019-04-22 | 2019-07-12 | 中国食品药品检定研究院 | 一种检测抗ox40抗体的方法及其应用 |
| CN113045654A (zh) * | 2019-12-27 | 2021-06-29 | 南开大学 | 抗ox40抗体及其用途 |
| CN113045655A (zh) * | 2019-12-27 | 2021-06-29 | 高诚生物医药(香港)有限公司 | 抗ox40抗体及其用途 |
| EP4130039A4 (en) * | 2020-03-23 | 2024-07-31 | Bio-Thera Solutions, Ltd. | DEVELOPMENT AND APPLICATION OF AN IMMUNE CELL ACTIVATOR |
| CN114014906B (zh) * | 2020-06-24 | 2024-01-12 | 夏尔巴生物技术(苏州)有限公司 | 一种利用阳离子交换层析纯化疏水性蛋白的方法 |
| CN111704671B (zh) * | 2020-08-19 | 2020-11-24 | 广东赛尔生物科技有限公司 | Ox40抗体及其在治疗癌症中的应用 |
| WO2023060244A1 (en) * | 2021-10-07 | 2023-04-13 | Lankenau Institute For Medical Research | Methods and compositions including novel antibodies for diagnosing covid-19 variants |
| CA3240585A1 (en) | 2021-12-17 | 2023-06-22 | Wenfeng Xu | Anti-ox40 antibodies, multispecific antibodies and methods of use |
| EP4448579A4 (en) | 2021-12-17 | 2026-02-18 | Shanghai Henlius Biotech Inc | ANTI-OX40 ANTIBODIES AND METHODS OF USE |
| CN114478789B (zh) * | 2021-12-20 | 2024-06-14 | 安徽安科生物工程（集团）股份有限公司 | 抗pd-l1与ox40双特异性抗体及其用途 |
| CN114966061B (zh) * | 2022-07-28 | 2022-10-21 | 中国食品药品检定研究院 | 一种抗ox40抗体的生物活性检测方法 |
| CN120476146A (zh) * | 2022-12-30 | 2025-08-12 | 甘李药业股份有限公司 | 抗ox40抗体及其应用 |
| AU2024322975A1 (en) * | 2023-08-04 | 2026-03-05 | Fortvita Biologics Inc. | Anti-ox40l antibody and use thereof |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4737456A (en) | 1985-05-09 | 1988-04-12 | Syntex (U.S.A.) Inc. | Reducing interference in ligand-receptor binding assays |
| IL85035A0 (en) | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
| DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
| EP0940468A1 (en) | 1991-06-14 | 1999-09-08 | Genentech, Inc. | Humanized antibody variable domain |
| GB9114948D0 (en) | 1991-07-11 | 1991-08-28 | Pfizer Ltd | Process for preparing sertraline intermediates |
| EP0604580A1 (en) | 1991-09-19 | 1994-07-06 | Genentech, Inc. | EXPRESSION IN E. COLI OF ANTIBODY FRAGMENTS HAVING AT LEAST A CYSTEINE PRESENT AS A FREE THIOL, USE FOR THE PRODUCTION OF BIFUNCTIONAL F(ab') 2? ANTIBODIES |
| US5789199A (en) | 1994-11-03 | 1998-08-04 | Genentech, Inc. | Process for bacterial production of polypeptides |
| US5840523A (en) | 1995-03-01 | 1998-11-24 | Genetech, Inc. | Methods and compositions for secretion of heterologous polypeptides |
| US6267958B1 (en) | 1995-07-27 | 2001-07-31 | Genentech, Inc. | Protein formulation |
| US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
| EP1997893A1 (en) | 1998-02-24 | 2008-12-03 | Sisters of Providence in Oregon | Compositions containing an OX-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| US7850962B2 (en) | 2004-04-20 | 2010-12-14 | Genmab A/S | Human monoclonal antibodies against CD20 |
| JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
| ES2720160T3 (es) | 2005-05-09 | 2019-07-18 | Ono Pharmaceutical Co | Anticuerpos monoclonales humanos contra muerte programada 1(PD-1) y métodos para tratar el cáncer usando anticuerpos dirigidos contra PD-1 solos o junto con otras sustancias inmunoterapéuticas |
| EP1881214A1 (en) | 2005-05-12 | 2008-01-23 | NSK Ltd. | Linear guide device |
| EA019344B1 (ru) | 2005-07-01 | 2014-03-31 | МЕДАРЕКС, Эл.Эл.Си. | Человеческие моноклональные антитела против лиганда-1 запрограммированной гибели клеток (pd-l1) и их применения |
| TWI461436B (zh) * | 2005-11-25 | 2014-11-21 | Kyowa Hakko Kirin Co Ltd | 人類ｃｄ１３４（ｏｘ４０）之人類單株抗體及其製造及使用方法 |
| CA2679399A1 (en) * | 2007-02-27 | 2008-09-04 | Genetech, Inc. | Antagonist ox40 antibodies and their use in the treatment of inflammatory and autoimmune diseases |
| JP5933894B2 (ja) | 2007-09-14 | 2016-06-15 | アディマブ， エルエルシー | 合理的に設計された、合成抗体ライブラリおよびその使用 |
| US8877688B2 (en) | 2007-09-14 | 2014-11-04 | Adimab, Llc | Rationally designed, synthetic antibody libraries and uses therefor |
| HUE032735T2 (en) | 2007-12-14 | 2017-10-30 | Bristol Myers Squibb Co | Binding molecules for the human OX40 receptor |
| EP2242773B1 (en) | 2008-02-11 | 2017-06-14 | Cure Tech Ltd. | Monoclonal antibodies for tumor treatment |
| EP2262837A4 (en) | 2008-03-12 | 2011-04-06 | Merck Sharp & Dohme | PD-1 BINDING PROTEINS |
| EP2328920A2 (en) | 2008-08-25 | 2011-06-08 | Amplimmune, Inc. | Targeted costimulatory polypeptides and methods of use to treat cancer |
| HUE065752T2 (hu) | 2008-12-09 | 2024-06-28 | Hoffmann La Roche | Anti-PD-L1 antitestek és felhasználásuk T-sejt funkció elõsegítésére |
| EP2504028A4 (en) | 2009-11-24 | 2014-04-09 | Amplimmune Inc | SIMULTANEOUS INHIBITION OF PD-L1 / PD-L2 |
| CN103080339B (zh) | 2010-07-15 | 2016-08-31 | 加利福尼亚大学董事会 | 用于诊断卒中及其致因的生物标志物 |
| KR102810907B1 (ko) | 2010-07-16 | 2025-05-21 | 아디맵 엘엘씨 | 항체 라이브러리 |
| PL2609118T3 (pl) | 2010-08-23 | 2017-07-31 | Board Of Regents, The University Of Texas System | Przeciwciała anty-OX40 i sposoby ich stosowania |
| NZ712903A (en) * | 2013-03-18 | 2018-07-27 | Biocerox Prod Bv | Humanized anti-cd134 (ox40) antibodies and uses thereof |
| CA2934028A1 (en) * | 2013-12-17 | 2015-06-25 | Genentech, Inc. | Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists |
| HRP20192285T1 (hr) | 2014-03-31 | 2020-03-06 | F. Hoffmann - La Roche Ag | Anti-ox40 protutijela i postupci uporabe |
| MX2017006320A (es) * | 2014-11-17 | 2017-08-10 | Genentech Inc | Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1. |
| PH12017502013B1 (en) * | 2015-05-07 | 2022-07-22 | Agenus Inc | Anti-ox40 antibodies and methods of use thereof |
| UY36687A (es) * | 2015-05-29 | 2016-11-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos contra ox40 y sus usos |
| EP3303399A1 (en) * | 2015-06-08 | 2018-04-11 | H. Hoffnabb-La Roche Ag | Methods of treating cancer using anti-ox40 antibodies |
| US20170000885A1 (en) * | 2015-06-08 | 2017-01-05 | Genentech, Inc. | Methods of treating cancer using anti-ox40 antibodies and pd-1 axis binding antagonists |
| EP3612209A4 (en) | 2017-04-20 | 2021-03-24 | The University of Chicago | METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER WITH MEC AFFINITY PEPTIDES RELATED TO IMMUNOTHERAPEUTIC ANTIBODIES |
-
2017
- 2017-03-25 CN CN201710185400.8A patent/CN108623686A/zh active Pending
-
2018
- 2018-03-23 CN CN201880020043.2A patent/CN110536903B/zh active Active
- 2018-03-23 EP EP18776775.1A patent/EP3604338A4/en not_active Withdrawn
- 2018-03-23 JP JP2019551983A patent/JP7046973B2/ja not_active Expired - Fee Related
- 2018-03-23 WO PCT/CN2018/080315 patent/WO2018177220A1/zh not_active Ceased
- 2018-03-23 CA CA3056972A patent/CA3056972A1/en active Pending
- 2018-03-23 US US16/496,019 patent/US11498972B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020515247A5 (enExample) | ||
| JP6518005B2 (ja) | Ｐｄ−ｌ１抗体 | |
| JP7425604B2 (ja) | 抗ｃｔｌａ４－抗ｐｄ－１二機能性抗体、その医薬組成物および使用 | |
| TWI821474B (zh) | Ｃｄ３抗體及其藥物用途 | |
| CN110291109B (zh) | 人程序性死亡受体pd-1的单克隆抗体及其片段 | |
| Maleki et al. | Future prospects of monoclonal antibodies as magic bullets in immunotherapy | |
| JPWO2019175223A5 (enExample) | ||
| JPWO2019175216A5 (enExample) | ||
| JPWO2019175224A5 (enExample) | ||
| JPWO2019175217A5 (enExample) | ||
| CN112969476B (zh) | 多特异性蛋白分子 | |
| JP2021518103A5 (enExample) | ||
| JPWO2019175220A5 (enExample) | ||
| JP2021531764A5 (enExample) | ||
| KR20190117493A (ko) | 항 pd-1 항체 및 그의 용도 | |
| FI3487882T3 (fi) | Gprc5d-vasta-aineita, bispesifisiä antigeeniä sitovia molekyylejä, jotka sitovat gprc5d:tä ja cd3:a, sekä niiden käyttötapoja | |
| JP2018531219A6 (ja) | Ｐｄ−ｌ１抗体 | |
| JP2019524693A5 (enExample) | ||
| JPWO2019175222A5 (enExample) | ||
| JPWO2019175215A5 (enExample) | ||
| JP2017535257A5 (enExample) | ||
| JP2018527919A5 (enExample) | ||
| JPWO2019175226A5 (enExample) | ||
| CN104903352A (zh) | 多价结合蛋白组合物 | |
| JP2020522280A5 (enExample) |